Approval Year
| Substance Class |
Mixture
Created
by
admin
on
Edited
Wed Apr 02 02:50:25 GMT 2025
by
admin
on
Wed Apr 02 02:50:25 GMT 2025
|
| Record UNII |
S134V96RPQ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C574
Created by
admin on Wed Apr 02 02:50:25 GMT 2025 , Edited by admin on Wed Apr 02 02:50:25 GMT 2025
|
||
|
FDA ORPHAN DRUG |
312610
Created by
admin on Wed Apr 02 02:50:25 GMT 2025 , Edited by admin on Wed Apr 02 02:50:25 GMT 2025
|
||
|
NCI_THESAURUS |
C20401
Created by
admin on Wed Apr 02 02:50:25 GMT 2025 , Edited by admin on Wed Apr 02 02:50:25 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
ROZROLIMUPAB
Created by
admin on Wed Apr 02 02:50:25 GMT 2025 , Edited by admin on Wed Apr 02 02:50:25 GMT 2025
|
PRIMARY | |||
|
C152271
Created by
admin on Wed Apr 02 02:50:25 GMT 2025 , Edited by admin on Wed Apr 02 02:50:25 GMT 2025
|
PRIMARY | |||
|
909402-77-3
Created by
admin on Wed Apr 02 02:50:25 GMT 2025 , Edited by admin on Wed Apr 02 02:50:25 GMT 2025
|
PRIMARY | |||
|
300000041371
Created by
admin on Wed Apr 02 02:50:25 GMT 2025 , Edited by admin on Wed Apr 02 02:50:25 GMT 2025
|
PRIMARY | |||
|
DB05209
Created by
admin on Wed Apr 02 02:50:25 GMT 2025 , Edited by admin on Wed Apr 02 02:50:25 GMT 2025
|
PRIMARY | |||
|
UU-166
Created by
admin on Wed Apr 02 02:50:25 GMT 2025 , Edited by admin on Wed Apr 02 02:50:25 GMT 2025
|
PRIMARY | |||
|
CHEMBL2107859
Created by
admin on Wed Apr 02 02:50:25 GMT 2025 , Edited by admin on Wed Apr 02 02:50:25 GMT 2025
|
PRIMARY | |||
|
S134V96RPQ
Created by
admin on Wed Apr 02 02:50:25 GMT 2025 , Edited by admin on Wed Apr 02 02:50:25 GMT 2025
|
PRIMARY |
All of the following components must be present:
UNSPECIFIED SUBSTANCE
(not present in database)
UNSPECIFIED SUBSTANCE
(not present in database)
UNSPECIFIED SUBSTANCE
(not present in database)
UNSPECIFIED SUBSTANCE
(not present in database)
UNSPECIFIED SUBSTANCE
(not present in database)
UNSPECIFIED SUBSTANCE
(not present in database)
UNSPECIFIED SUBSTANCE
(not present in database)
UNSPECIFIED SUBSTANCE
(not present in database)
UNSPECIFIED SUBSTANCE
(not present in database)
UNSPECIFIED SUBSTANCE
(not present in database)
UNSPECIFIED SUBSTANCE
(not present in database)
UNSPECIFIED SUBSTANCE
(not present in database)
UNSPECIFIED SUBSTANCE
(not present in database)
UNSPECIFIED SUBSTANCE
(not present in database)
UNSPECIFIED SUBSTANCE
(not present in database)
UNSPECIFIED SUBSTANCE
(not present in database)
UNSPECIFIED SUBSTANCE
(not present in database)
UNSPECIFIED SUBSTANCE
(not present in database)
UNSPECIFIED SUBSTANCE
(not present in database)
UNSPECIFIED SUBSTANCE
(not present in database)
UNSPECIFIED SUBSTANCE
(not present in database)
UNSPECIFIED SUBSTANCE
(not present in database)
UNSPECIFIED SUBSTANCE
(not present in database)
UNSPECIFIED SUBSTANCE
(not present in database)
UNSPECIFIED SUBSTANCE
(not present in database)
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
TARGET->LIGAND |
proposed that anti-D Ig’s cause IgG antibody coating and opsonization of RBC’s, leading to FcR-mediatied binding to macrophages and other phagocytic cells. Used as a decoy to protect antibody-coated platelets.
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
Agent Modifications
| Modification Process | Modification Role | Modification Type | Amount | Fragment Name | Fragment ID |
|---|---|---|---|---|---|
| IMMUNOLOGICAL | BLOOD GROUP RH(D) POLYPEPTIDE | 16YYC73841 |